Digestive system involvement in cystic fibrosis

Pancreatology

Volumn 2, Issue 1, 2002, Pages 12-16

  Modolell, Inés ^a,b   Guarner, L ^a   Malagelada, J R ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Biliary tract; Cystic fibrosis; Digestive system; Liver; Pancreas

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ACUTE PANCREATITIS; AUTOSOMAL RECESSIVE DISORDER; CHROMOSOME 7; CHROMOSOME MUTATION; CLINICAL FEATURE; CONSTIPATION; CYSTIC FIBROSIS; ENZYME THERAPY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GENOTYPE; HEPATOBILIARY SYSTEM; HUMAN; LIVER DISEASE; NUTRITIONAL STATUS; PEDIATRICIAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 0036279066     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000049442     Document Type: Review

References (42)

1. Cystic fibrosis
2. The changing epidemiology of cystic fibrosis
3. The diagnosis of cystic fibrosis: A consensus statement
4. Structure and function of the CFTR channel
5. CFTR: Mechanism of anion conduction
6. Control of the CFTR channel gating by phosphorylation and nucleotide hydrolysis
7. CFTR is a conductance regulator as well as a chloride channel
8. Identification of the cystic fibrosis gene: Genetic analysis
9. Genotype and phenotype in cystic fibrosis
10. Genetic determination of exocrine pancreatic function in cystic fibrosis
11. Recurrent acute pancreatitis in patients with cystic fibrosis with normal pancreatic enzymes
12. Gastrointestinal, liver and pancreatic involvement in adult patients with cystic fibrosis
13. Genetic determination of diabetes mellitus in patients with cystic fibrosis
14. Clinical and genetic risk factors for cystic fibrosis-related liver disease
15. Is meconium ileus genetically determined or associated with a more severe evolution of cystic fibrosis?
16. Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas
17. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency
18. Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years
19. Clinical characteristics of 16 cystic fibrosis patients with the missense mutation R334W, a pancreatic insufficiency mutation with variable age of onset and interfamilial clinical differences
20. Relapsing pancreatitis as initial manifestation of cystic fibrosis in a young man without pulmonary disease
21. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis
22. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis
23. Islet autoantibodies and insulin dependent diabetes mellitus in cystic fibrosis
24. Insulin resistance is associated with decreased clinical status in cystic fibrosis
25. Cystic fibrosis: Present and future
26. Constipation and meconium ileus equivalent in patients with cystic fibrosis
27. Meconium ileus equivalent
28. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes
29. Fibrosing colonopathy in cystic fibrosis: Results of a case-control study
30. High-dose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis
31. Hepatic changes in young infants with cystic fibrosis: Possible relation to focal biliary cirrhosis
32. Prevalence of liver disease in cystic fibrosis
33. Analysis of risk factors for the development of liver disease associated with cystic fibrosis
34. The evolution of liver disease in cystic fibrosis
35. Liver and biliary problems in cystic fibrosis
36. Liver involvement in cystic fibrosis
37. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile excretion and liver morphology in cystic fibrosis-associated liver disease
38. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial
39. Liver transplantation for hepatic cirrhosis in cystic fibrosis
40. Nutrition in adults with cystic fibrosis
41. Increased resting energy expenditure in cystic fibrosis
42. Energy expenditure of patients with cystic fibrosis